0.20Open0.20Pre Close0 Volume10 Open Interest10.00Strike Price0.00Turnover289.79%IV57.81%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type-0.0331Delta0.0059Gamma116.15Leverage Ratio-0.0355Theta-0.0003Rho-3.84Eff Leverage0.0032Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet